Projects
Morphological, molecular and functional insights into the cardiovascular complications of autosomal dominant polycystic kidney disease Ghent University
Autosomal dominant polycystic kidney disease (ADPKD) occurs upon mutations in either the PKD1 or PKD2 gene and represents the most common monogenetic disease (incidence 1:500-1:1000). Frequent and dire complications of APDKD are cardiovascular anomalies, such as intracranial aneurysms, which upon rupture are life-threatening. Here, I intend to further exploit a CRISPR/Cas9-mediated animal model for ADPKD to obtain morphological, molecular and ...
Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception. KU Leuven
Cardiovascular disease (CVD) and lung cancer (LC) are leading causes of deaths and intertwined chronic inflammatory processes associated with metabolism reprogramming, clonal hematopoiesis of indeterminate potential (CHIP), intestinal dysbiosis, and maladaptive immunity. CVD prone-tobacco users exhibit a 1-2% yearly incidence of LC. Low dose computed tomography screening programs reduce LC mortality by 20%. Beyond epidemiological scores, risk ...
Integrated silicon photonics for Cardiovascular Disease monitoring Ghent University
The rationale for Medtronic and partners to propose the InSiDe project is the unmet need of the medical community for reliable, non-invasive, cheap and easy-to-use tools able to identify and characterize different stages of cardiovascular diseases. Solving this need ensures the early adoption of the appropriate therapies, dramatically reduces healthcare costs and importantly, improves patient outcome. In fact, monitoring arterial stiffness by ...
Tissue-specific induction of autophagy as an innovative therapeutic strategy in cardiovascular and metabolic disease. (CARDIOPHAGY). University of Antwerp
Study of the vascular alterations in the pathophysiology of Non-Alcoholic Steatohepatitis and of the reciprocal causal role of Non-Alcoholic Steatohepatitis in cardiovascular disease. University of Antwerp
The use of metformin in the battle against chronic kidney disease and its cardiovascular complications. University of Antwerp
CardioReGenix: Development of Next-Generation Gene Therapies for Cardiovascular Disease (OZR EU Bonus). Vrije Universiteit Brussel
CardioReGenix: Development of Next-Generation Gene Therapies for Cardiovascular Disease Vrije Universiteit Brussel
WHO estimates 17.7 million people die each year from cardiovascular disease (CVD), an estimated 31% of all deaths worldwide. While progress with conventional treatments is making incremental gains, there remains a need to develop innovative therapeutic approaches. Gene therapy has gained significant momentum, mainly for treatment of rare monogenetic diseases. Marketing authorization for gene therapy products has not impacted ...